Administration of FTY720 before infection prevented viral spread and consequently led to less LCMV-specific CD8+ T cell number in the iLNs in comparison to the untreated group, whereas the group that received FTY720 starting from day 3 after infection and have already viral distribution in iLNs showed similar number of LCMV-specific CD8+ T cells to the untreated one (Figure 5G). This evidence concerns the gene CD8A and infection.